This was the stock's second consecutive day of losses.

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new ...

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold ...

Kenvue Inc. has announced the appointment of Amit Banati as chief financial officer, effective today. He will be responsible ...

Barclays analyst Lauren Lieberman maintained a Hold rating on Kenvue, Inc. (KVUE – Research Report) today and set a price target of $23.00. The company’s shares closed last Fr ...

Self care segment revenue growth updated Consumer health company Kenvue Inc. (NYSE:KVUE) on Thursday reported first-quarter ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The leadership change comes at the end of a week in which the California-based toymaker landed squarely in the crosshairs of ...

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

The Neutrogena and Aveeno owner has also increased its 2025 full-year outlook to reflect the impact of costs associated with ...

Kenvue named Kellanova Chief Financial Officer Amit Banati to that role at the over-the-counter drug maker, replacing current financial chief Paul Ruh, effective May 12. Banati has worked in executive ...

Kenvue KVUE1.58%increase; green up pointing triangle, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial ...